0
Détail de l'indexation
TU 4.1. : MDR (Multi Drug Resistance) / XDR (X-treme Drug Resistance) |
Ouvrages de la bibliothèque en indexation TU 4.1. (7)
Ajouter le résultat dans votre panier Affiner la rechercheEuropean Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following new World Health Organization recommendations / Giovanni Battista Migliori (2018)
Titre : European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following new World Health Organization recommendations Type de document : document électronique Auteurs : Giovanni Battista Migliori, Auteur ; Giovanni Sotgiu, Auteur Editeur : European Respiratory Society (ERS) Année de publication : 2018 Collection : European Respiratory Journal num. 52 Importance : 1801617 Présentation : tab. Langues : Anglais (eng) Catégories : [DIVERS] association:association internationale:Organisation Mondiale de la Santé
[DIVERS] géographie:Europe
[TUBER] prévention:recommandation
[TUBER] traitement:résistance:multirésistance
[TUBER] traitement:traitement curatif:médicament spécial MDRIndex. décimale : TU 4.1. MDR (Multi Drug Resistance) / XDR (X-treme Drug Resistance) Résumé : The key changes to treatment of multidrug-resistant tuberculosis (World Health Organization, August 2018) should be taken into account when applying standard 12 of the European Union Standards for Tuberculosis Care. En ligne : https://doi.org/10.1183/13993003.01617-2018 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10941 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Fluoroquinolone resistance in multidrugresistant Mycobacterium tuberculosis independent of fluoroquinolone use Type de document : document électronique Auteurs : Yang Che, Auteur ; Qifa Song, Auteur ; Tianchi Yang, Auteur ; Guohua Ping, Auteur ; Mei Yu, Auteur Editeur : European Respiratory Society (ERS) Année de publication : 2017 Collection : European Respiratory Journal num. 50 Importance : 1701633 Présentation : tab. Langues : Anglais (eng) Catégories : [TUBER] traitement:résistance:multirésistance
[TUBER] traitement:traitement curatif:médicament spécial MDRIndex. décimale : TU 4.1. MDR (Multi Drug Resistance) / XDR (X-treme Drug Resistance) En ligne : https://doi.org/10.1183/13993003.01633-2017 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10931 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Les origines de la multi-résistance dévoilées / Luc Ruidant in Le journal du médecin, 2396 (27 février 2015)
Titre : Les origines de la multi-résistance dévoilées Type de document : texte imprimé Auteurs : Luc Ruidant, Intervieweur ; Maryse Fauville, Personne interviewée Année de publication : 2015 Article en page(s) : p.10 Langues : Français (fre) Catégories : [TUBER] étude:épidémiologie:génétique
[TUBER] traitement:résistance
[TUBER] traitement:résistance:multirésistance
[TUBER] type de tuberculose:tuberculose-maladieIndex. décimale : TU 4.1. MDR (Multi Drug Resistance) / XDR (X-treme Drug Resistance) Résumé : Grâce à leurs travaux génétiques et chronologiques portant sur la plus grande collection de bacilles tuberculeux étudiée à ce jour, les chercheurs ont mis en évidence des mutations et des gènes qui devraient permettre des avancées en matière de diagnostic et de traitement. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=3267
in Le journal du médecin > 2396 (27 février 2015) . - p.10[article]Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité PAEE DEP Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis : a prospective cohort study Type de document : document électronique Auteurs : Keertan Dheda, Auteur ; Jason D. Limberis, Auteur ; Elize Pietersen, Auteur Editeur : Lancet Année de publication : 2017 Collection : The Lancet Respiratory Medicine, ISSN 2213-2600 num. vol. 5 Importance : p.269-281 Présentation : ill. ; graph. ; tab. Langues : Anglais (eng) Catégories : [TUBER] étude:épidémiologie
[TUBER] traitement:résistance:multirésistance
[TUBER] traitement:traitement curatif
[DIVERS] géographie:Afrique:Afrique subsaharienne:Afrique du SudIndex. décimale : TU 4.1. MDR (Multi Drug Resistance) / XDR (X-treme Drug Resistance) Résumé : Background
The emergence of programmatically incurable tuberculosis threatens to destabilise control efforts. The aim of this study was to collect prospective patient-level data to inform treatment and containment strategies.
Methods
In a prospective cohort study, 273 South African patients with extensively drug-resistant tuberculosis, or resistance beyond extensively drug-resistant tuberculosis, were followed up over a period of 6 years. Transmission dynamics, infectiousness, and drug susceptibility were analysed in a subset of patients from the Western Cape using whole-genome sequencing (WGS; n=149), a cough aerosol sampling system (CASS; n=26), and phenotypic testing for 18 drugs (n=179).
Findings
Between Oct 1, 2008, and Oct 31, 2012, we enrolled and followed up 273 patients for a median of 20·3 months (IQR 9·6–27·8). 203 (74%) had programmatically incurable tuberculosis and unfavourable outcomes (treatment failure, relapse, default, or death despite treatment with a regimen based on capreomycin, aminosalicylic acid, or both). 172 (63%) patients were discharged home, of whom 104 (60%) had an unfavourable outcome. 54 (31%) home-discharged patients had failed treatment, with a median time to death after discharge of 9·9 months (IQR 4·2–17·4). 35 (20%) home-discharged cases were smear-positive at discharge. Using CASS, six (23%) of 26 home-discharged cases with data available expectorated infectious culture-positive cough aerosols in the respirable range (<5 μm), and most reported inter-person contact with suboptimal protective mask usage. WGS identified 17 (19%) of the 90 patients (with available sequence data) that were discharged home before the diagnosis of 20 downstream cases of extensively drug-resistant tuberculosis with almost identical sequencing profiles suggestive of community-based transmission (five or fewer single nucleotide polymorphisms different and with identical resistance-encoding mutations for 14 drugs). 11 (55%) of these downstream cases had HIV co-infection and ten (50%) had died by the end of the study. 22 (56%) of 39 isolates in patients discharged home after treatment failure were resistant to eight or more drugs. However, five (16%) of 31 isolates were susceptible to rifabutin and more than 90% were likely to be sensitive to linezolid, bedaquiline, and delamanid.
Interpretation
More than half of the patients with programmatically incurable tuberculosis were discharged into the community where they remained for an average of 16 months, were at risk of expectorating infectious cough aerosols, and posed a threat of transmission of extensively drug-resistant tuberculosis. Urgent action, including appropriate containment strategies, is needed to address this situation. Access to delamanid, bedaquiline, linezolid, and rifabutin, when appropriate, must be accelerated along with comprehensive drug susceptibility testing.En ligne : http://dx.doi.org/10.1016/S2213-2600(16)30433-7 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10909 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis Type de document : document électronique Auteurs : Paolo Miotto, Auteur ; Belay Tessema, Auteur ; Elisa Tagliani, Auteur Editeur : European Respiratory Society (ERS) Année de publication : 2017 Collection : European Respiratory Journal num. 50 Importance : 1701354 Présentation : graph. ; tab. Langues : Anglais (eng) Catégories : [TUBER] étude:épidémiologie:génétique
[TUBER] traitement:résistance:multirésistanceIndex. décimale : TU 4.1. MDR (Multi Drug Resistance) / XDR (X-treme Drug Resistance) Résumé : A clear understanding of the genetic basis of antibiotic resistance in Mycobacterium tuberculosis is required to accelerate the development of rapid drug susceptibility testing methods based on genetic sequence.
Raw genotype–phenotype correlation data were extracted as part of a comprehensive systematic review to develop a standardised analytical approach for interpreting resistance associated mutations for rifampicin, isoniazid, ofloxacin/levofloxacin, moxifloxacin, amikacin, kanamycin, capreomycin, streptomycin, ethionamide/prothionamide and pyrazinamide. Mutation frequencies in resistant and susceptible isolates were calculated, together with novel statistical measures to classify mutations as high, moderate, minimal or indeterminate confidence for predicting resistance.
We identified 286 confidence-graded mutations associated with resistance. Compared to phenotypic methods, sensitivity (95% CI) for rifampicin was 90.3% (89.6–90.9%), while for isoniazid it was 78.2% (77.4–79.0%) and their specificities were 96.3% (95.7–96.8%) and 94.4% (93.1–95.5%), respectively. For second-line drugs, sensitivity varied from 67.4% (64.1–70.6%) for capreomycin to 88.2% (85.1–90.9%) for moxifloxacin, with specificity ranging from 90.0% (87.1–92.5%) for moxifloxacin to 99.5% (99.0–99.8%) for amikacin.
This study provides a standardised and comprehensive approach for the interpretation of mutations as predictors of M. tuberculosis drug-resistant phenotypes. These data have implications for the clinical interpretation of molecular diagnostics and next-generation sequencing as well as efficient individualised therapy for patients with drug-resistant tuberculosis.En ligne : https://doi.org/10.1183/13993003.01354-2017 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10930 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis Type de document : document électronique Auteurs : Keertan Dheda, Auteur ; Tawanda Gumbo, Auteur ; Gary Maartens, Auteur Editeur : Lancet Année de publication : 2017 Collection : The Lancet Respiratory Medicine, ISSN 2213-2600 num. vol. 5 Importance : p.291-360 Présentation : ill. ; graph. ; tab. Langues : Anglais (eng) Catégories : [TUBER] étude:épidémiologie
[TUBER] traitement:résistance:multirésistance
[TUBER] traitement:traitement curatif
[DIVERS] géographie:Afrique:Afrique subsaharienne:Afrique du SudIndex. décimale : TU 4.1. MDR (Multi Drug Resistance) / XDR (X-treme Drug Resistance) Résumé : Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world including Africa and Asia. Although tuberculosis control has been effective in some regions of the world, these gains are threatened by the increasing burden of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. XDR tuberculosis has evolved in several tuberculosis-endemic countries to drug-incurable or programmatically incurable tuberculosis (totally drug-resistant tuberculosis). This poses several challenges similar to those encountered in the pre-chemotherapy era, including the inability to cure tuberculosis, high mortality, and the need for alternative methods to prevent disease transmission. This phenomenon mirrors the worldwide increase in antimicrobial resistance and the emergence of other MDR pathogens, such as malaria, HIV, and Gram-negative bacteria. MDR and XDR tuberculosis are associated with high morbidity and substantial mortality, are a threat to health-care workers, prohibitively expensive to treat, and are therefore a serious public health problem. In this Commission, we examine several aspects of drug-resistant tuberculosis. The traditional view that acquired resistance to antituberculous drugs is driven by poor compliance and programmatic failure is now being questioned, and several lines of evidence suggest that alternative mechanisms—including pharmacokinetic variability, induction of efflux pumps that transport the drug out of cells, and suboptimal drug penetration into tuberculosis lesions—are likely crucial to the pathogenesis of drug-resistant tuberculosis. These factors have implications for the design of new interventions, drug delivery and dosing mechanisms, and public health policy. We discuss epidemiology and transmission dynamics, including new insights into the fundamental biology of transmission, and we review the utility of newer diagnostic tools, including molecular tests and next-generation whole-genome sequencing, and their potential for clinical effectiveness. Relevant research priorities are highlighted, including optimal medical and surgical management, the role of newer and repurposed drugs (including bedaquiline, delamanid, and linezolid), pharmacokinetic and pharmacodynamic considerations, preventive strategies (such as prophylaxis in MDR and XDR contacts), palliative and patient-orientated care aspects, and medicolegal and ethical issues. En ligne : http://dx.doi.org/10.1016/S2213-2600(17)30079-6 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10910 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Type de document : document électronique Auteurs : Dennis Falzon, Auteur ; Ernesto Jaramillo, Auteur ; Christopher Gilpin, Auteur ; Karin Weyer, Auteur Editeur : European Respiratory Society (ERS) Année de publication : 2017 Collection : European Respiratory Journal num. 49 Importance : 1700173 Présentation : ill. Langues : Anglais (eng) Catégories : [TUBER] traitement:résistance:multirésistance
[TUBER] traitement:traitement curatif
[TUBER] traitement:traitement curatif:médicament spécial MDRIndex. décimale : TU 4.1. MDR (Multi Drug Resistance) / XDR (X-treme Drug Resistance) En ligne : https://doi.org/10.1183/13993003.00173-2017 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10914 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
